{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T12:57:48Z","timestamp":1788872268709,"version":"build-2803163510"},"reference-count":33,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2012,10,1]],"date-time":"2012-10-01T00:00:00Z","timestamp":1349049600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2012,10,1]],"date-time":"2012-10-01T00:00:00Z","timestamp":1349049600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"name":"Novo Nordisk Inc"},{"DOI":"10.13039\/100006153","name":"Ladies Leukemia League Inc","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100006153","id-type":"DOI","asserted-by":"crossref"}]},{"name":"University of Texas MD Anderson Cancer Center, Division of Internal Medicine Multidisciplinary Research Program"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinical-lymphoma-myeloma-leukemia.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lymphoma Myeloma and Leukemia"],"published-print":{"date-parts":[[2012,10]]},"DOI":"10.1016\/j.clml.2012.05.004","type":"journal-article","created":{"date-parts":[[2012,6,1]],"date-time":"2012-06-01T02:08:41Z","timestamp":1338516521000},"page":"355-362","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":33,"title":["A Randomized Controlled Trial of an Intensive Insulin Regimen in Patients With Hyperglycemic Acute Lymphoblastic Leukemia"],"prefix":"10.1016","volume":"12","author":[{"given":"Khanh","family":"Vu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naifa","family":"Busaidy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria E.","family":"Cabanillas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marina","family":"Konopleva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan","family":"Faderl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deborah A.","family":"Thomas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan","family":"O'Brien","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristine","family":"Broglio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joe","family":"Ensor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carmen","family":"Escalante","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Andreeff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hagop","family":"Kantarjian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victor","family":"Lavis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sai-Ching Jim","family":"Yeung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clml.2012.05.004_bib1","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1054\/bjoc.2000.1582","article-title":"Prospective study of colorectal cancer risk and physical activity, diabetes, blood glucose and BMI: exploring the hyperinsulinaemia hypothesis","volume":"84","author":"Nilsen","year":"2001","journal-title":"Br J Cancer"},{"key":"10.1016\/j.clml.2012.05.004_bib2","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.2337\/diacare.26.4.1047","article-title":"Mortality from site-specific malignancies in type 2 diabetic patients from Verona","volume":"26","author":"Verlato","year":"2003","journal-title":"Diabetes Care"},{"key":"10.1016\/j.clml.2012.05.004_bib3","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1038\/ncponc0062","article-title":"Therapy insight: influence of type 2 diabetes on the development, treatment and outcomes of cancer","volume":"2","author":"Richardson","year":"2005","journal-title":"Nat Clin Pract Oncol"},{"key":"10.1016\/j.clml.2012.05.004_bib4","doi-asserted-by":"crossref","first-page":"1160","DOI":"10.1093\/aje\/kwh161","article-title":"Diabetes mellitus as a predictor of cancer mortality in a large cohort of US adults","volume":"159","author":"Coughlin","year":"2004","journal-title":"Am J Epidemiol"},{"key":"10.1016\/j.clml.2012.05.004_bib5","doi-asserted-by":"crossref","first-page":"1986","DOI":"10.1002\/ijc.22532","article-title":"Less aggressive treatment and worse overall survival in cancer patients with diabetes: a large population based analysis","volume":"120","author":"van de Poll-Franse","year":"2007","journal-title":"Int J Cancer"},{"key":"10.1016\/j.clml.2012.05.004_bib6","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1200\/JCO.2000.18.3.547","article-title":"Results of treatment with hyper-CVAD, a dose-intensive regimen, in adult acute lymphocytic leukemia","volume":"18","author":"Kantarjian","year":"2000","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2012.05.004_bib7","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1002\/cncr.20071","article-title":"Relation between the duration of remission and hyperglycemia during induction chemotherapy for acute lymphocytic leukemia with a hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone\/methotrexate-cytarabine regimen","volume":"100","author":"Weiser","year":"2004","journal-title":"Cancer"},{"key":"10.1016\/j.clml.2012.05.004_bib8","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1210\/jcem.87.3.8341","article-title":"Hyperglycemia: an independent marker of in-hospital mortality in patients with undiagnosed diabetes","volume":"87","author":"Umpierrez","year":"2002","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.clml.2012.05.004_bib9","doi-asserted-by":"crossref","first-page":"937","DOI":"10.2337\/diabetes.48.5.937","article-title":"Hyperglycemia and cardiovascular disease in type 2 diabetes","volume":"48","author":"Laakso","year":"1999","journal-title":"Diabetes"},{"key":"10.1016\/j.clml.2012.05.004_bib10","doi-asserted-by":"crossref","first-page":"2563","DOI":"10.1001\/jama.287.19.2563","article-title":"Effect of intensive therapy on the microvascular complications of type 1 diabetes mellitus","volume":"287","year":"2002","journal-title":"JAMA"},{"key":"10.1016\/j.clml.2012.05.004_bib11","first-page":"977","article-title":"The Diabetes Control and Complications Trial Research Group","volume":"329","year":"1993","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clml.2012.05.004_bib12","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.1056\/NEJMoa0806470","article-title":"10-Year follow-up of intensive glucose control in type 2 diabetes","volume":"359","author":"Holman","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clml.2012.05.004_bib13","doi-asserted-by":"crossref","first-page":"2643","DOI":"10.1056\/NEJMoa052187","article-title":"Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes","volume":"353","author":"Nathan","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clml.2012.05.004_bib14","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.1056\/NEJMoa011300","article-title":"Intensive insulin therapy in the critically ill patients","volume":"345","author":"van den Berghe","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clml.2012.05.004_bib15","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1182\/blood.V112.11.904.904","article-title":"Effect of tight control of blood glucose during hyper-CVAD chemotherapy for acute lymphocytic leukemia","volume":"112","author":"Vu","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.clml.2012.05.004_bib16","doi-asserted-by":"crossref","first-page":"6330","DOI":"10.1182\/blood-2008-04-151860","article-title":"Prognostic significance of CD20 expression in adults with de novo precursor B-lineage acute lymphoblastic leukemia","volume":"113","author":"Thomas","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.clml.2012.05.004_bib17","doi-asserted-by":"crossref","first-page":"4642","DOI":"10.1210\/jc.2001-011949","article-title":"Ethnic differences in C-peptide\/insulin\/glucose dynamics in young pregnant women","volume":"87","author":"Chen","year":"2002","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.clml.2012.05.004_bib18","doi-asserted-by":"crossref","first-page":"37747","DOI":"10.1074\/jbc.M105796200","article-title":"Gleevec (STI571) influences metabolic enzyme activities and glucose carbon flow toward nucleic acid and fatty acid synthesis in myeloid tumor cells","volume":"276","author":"Boren","year":"2001","journal-title":"J Biol Chem"},{"key":"10.1016\/j.clml.2012.05.004_bib19","doi-asserted-by":"crossref","first-page":"9","DOI":"10.2337\/diab.23.1.9","article-title":"Impaired leukocyte function in patients with poorly controlled diabetes","volume":"23","author":"Bagdade","year":"1974","journal-title":"Diabetes"},{"key":"10.1016\/j.clml.2012.05.004_bib20","first-page":"763","article-title":"Postload plasma glucose concentration and 27-year prostate cancer mortality (United States)","volume":"12","author":"Gapstur","year":"2001","journal-title":"Cancer Causes Control"},{"key":"10.1016\/j.clml.2012.05.004_bib21","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1200\/JCO.2002.20.1.42","article-title":"Fasting insulin and outcome in early-stage breast cancer: results of a prospective cohort study","volume":"20","author":"Goodwin","year":"2002","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2012.05.004_bib22","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1200\/JCO.2003.07.125","article-title":"Impact of diabetes mellitus on outcomes in patients with colon cancer","volume":"21","author":"Meyerhardt","year":"2003","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2012.05.004_bib23","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1111\/j.1582-4934.2010.01083.x","article-title":"The impact of type 2 diabetes and antidiabetic drugs on cancer cell growth","volume":"15","author":"Feng","year":"2011","journal-title":"J Cell Mol Med"},{"key":"10.1016\/j.clml.2012.05.004_bib24","doi-asserted-by":"crossref","first-page":"10804","DOI":"10.1158\/0008-5472.CAN-07-2310","article-title":"Metformin inhibits mammalian target of rapamycin-dependent translation initiation in breast cancer cells","volume":"67","author":"Dowling","year":"2007","journal-title":"Cancer Res"},{"key":"10.1016\/j.clml.2012.05.004_bib25","doi-asserted-by":"crossref","first-page":"6745","DOI":"10.1158\/0008-5472.CAN-06-4447","article-title":"Systemic treatment with the antidiabetic drug metformin selectively impairs p53-deficient tumor cell growth","volume":"67","author":"Buzzai","year":"2007","journal-title":"Cancer Res"},{"key":"10.1016\/j.clml.2012.05.004_bib26","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.1007\/s00018-007-7080-4","article-title":"Dual antiglioma action of metformin: cell cycle arrest and mitochondria-dependent apoptosis","volume":"64","author":"Isakovic","year":"2007","journal-title":"Cell Mol Life Sci"},{"key":"10.1016\/j.clml.2012.05.004_bib27","doi-asserted-by":"crossref","first-page":"7192","DOI":"10.3748\/wjg.14.7192","article-title":"Metformin induces apoptosis of pancreatic cancer cells","volume":"14","author":"Wang","year":"2008","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.clml.2012.05.004_bib28","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1517\/13543784.14.6.557","article-title":"Peroxisome proliferator-activated receptor-gamma ligands for the treatment of breast cancer","volume":"14","author":"Fenner","year":"2005","journal-title":"Expert Opin Investig Drugs"},{"key":"10.1016\/j.clml.2012.05.004_bib29","doi-asserted-by":"crossref","first-page":"268","DOI":"10.4161\/cc.8.2.7584","article-title":"Thiazolidinediones regulate expression of cell cycle proteins in human prostate cancer cells via PPARgamma-dependent and PPARgamma-independent pathways","volume":"8","author":"Lyles","year":"2009","journal-title":"Cell Cycle"},{"key":"10.1016\/j.clml.2012.05.004_bib30","doi-asserted-by":"crossref","first-page":"441","DOI":"10.3748\/wjg.15.441","article-title":"Suppression of pancreatic carcinoma growth by activating peroxisome proliferator-activated receptor gamma involves angiogenesis inhibition","volume":"15","author":"Dong","year":"2009","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.clml.2012.05.004_bib31","doi-asserted-by":"crossref","first-page":"403","DOI":"10.2119\/2008-00021.Papageorgiou","article-title":"Rosiglitazone attenuates insulin-like growth factor 1 receptor survival signaling in PC-3 cells","volume":"14","author":"Papageorgiou","year":"2008","journal-title":"Mol Med"},{"key":"10.1016\/j.clml.2012.05.004_bib32","doi-asserted-by":"crossref","first-page":"90404","DOI":"10.1155\/2008\/904041","article-title":"Rosiglitazone inhibits adrenocortical cancer cell proliferation by interfering with the IGF-IR intracellular signaling","volume":"2008","author":"Cantini","year":"2008","journal-title":"PPAR Res"},{"key":"10.1016\/j.clml.2012.05.004_bib33","doi-asserted-by":"crossref","first-page":"2390","DOI":"10.1002\/ijc.21799","article-title":"Increased PTEN expression due to transcriptional activation of PPARgamma by lovastatin and rosiglitazone","volume":"118","author":"Teresi","year":"2006","journal-title":"Int J Cancer"}],"container-title":["Clinical Lymphoma Myeloma and Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265012000857?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265012000857?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T00:22:28Z","timestamp":1761870148000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2152265012000857"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,10]]},"references-count":33,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2012,10]]}},"alternative-id":["S2152265012000857"],"URL":"https:\/\/doi.org\/10.1016\/j.clml.2012.05.004","relation":{},"ISSN":["2152-2650"],"issn-type":[{"value":"2152-2650","type":"print"}],"subject":[],"published":{"date-parts":[[2012,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A Randomized Controlled Trial of an Intensive Insulin Regimen in Patients With Hyperglycemic Acute Lymphoblastic Leukemia","name":"articletitle","label":"Article Title"},{"value":"Clinical Lymphoma Myeloma and Leukemia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clml.2012.05.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2012 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}